Top Page
Clover Corporation Limited
(Sydney:CLV)
Clover Corporation Limited (CLV) vs. iShares MSCI Australia ETF (EWA)
Clover Corporation Limited Business Overview & Revenue Model
Clover Corporation Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 86.00M | 86.00M | 62.21M | 79.88M | 70.66M | 60.51M |
| Gross Profit | 26.17M | 26.17M | 16.86M | 23.74M | 21.66M | 18.24M |
| EBITDA | 11.78M | 12.24M | 3.98M | 10.01M | 11.66M | 10.23M |
| Net Income | 7.01M | 7.01M | 1.51M | 6.21M | 7.13M | 6.00M |
Balance Sheet | ||||||
| Total Assets | 86.80M | 86.80M | 84.39M | 86.20M | 90.77M | 78.73M |
| Cash, Cash Equivalents and Short-Term Investments | 8.68M | 8.68M | 12.26M | 9.44M | 10.11M | 9.09M |
| Total Debt | 2.42M | 2.42M | 10.39M | 11.71M | 12.08M | 14.19M |
| Total Liabilities | 14.57M | 14.57M | 17.32M | 19.05M | 27.73M | 20.32M |
| Stockholders Equity | 72.23M | 72.23M | 67.07M | 67.15M | 63.04M | 58.42M |
Cash Flow | ||||||
| Free Cash Flow | 6.95M | 6.95M | 6.13M | 5.10M | 4.51M | 6.40M |
| Operating Cash Flow | 8.29M | 8.29M | 8.45M | 6.74M | 5.93M | 8.23M |
| Investing Cash Flow | -1.34M | -1.34M | -2.97M | -2.53M | -1.43M | -1.83M |
| Financing Cash Flow | -10.52M | -10.52M | -2.66M | -4.88M | -3.49M | -6.55M |
Clover Corporation Limited Technical Analysis
Clover Corporation Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$128.59M | 19.05 | 10.07% | 2.19% | 38.25% | 361.54% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | AU$125.18M | 21.77 | 13.97% | ― | 28.66% | ― | |
43 Neutral | AU$33.11M | 38.26 | ― | ― | 6.76% | ― | |
38 Underperform | AU$26.76M | -4.86 | -20.54% | ― | 13.92% | 36.28% | |
38 Underperform | AU$19.45M | -4.79 | -29.43% | ― | 102.21% | 69.47% | |
31 Underperform | AU$4.50M | -0.64 | ― | ― | -21.84% | 79.99% |
Clover Corporation Limited Corporate Events
Clover Corporation Limited announced a change in the director’s interest, specifically involving Peter Davey. The change reflects an increase in the number of performance rights held directly by the director, with 529,638 performance rights acquired and 255,199 disposed of, resulting in a total of 1,361,706 performance rights held. This adjustment in holdings may indicate strategic positioning or confidence in the company’s future performance, potentially impacting stakeholders’ perceptions and the company’s market positioning.
Clover Corporation Limited held its Annual General Meeting on November 18, 2025, where several key resolutions were passed. The shareholders approved the adoption of the remuneration report, re-elected Dr. Simon Green and elected Ms. Fiona Pearse as directors, approved the acquisition of performance rights for the Managing Director, endorsed the long-term incentive plan, and adopted a new constitution. These decisions reflect the company’s strategic focus on governance and incentive alignment, potentially impacting its operational efficiency and stakeholder engagement positively.
Clover Corporation Limited reported a strong financial year in FY25, marked by a significant increase in sales and improved financial performance due to a successful diversification strategy. The company achieved notable milestones, including the commissioning of a fish oil extraction facility in Ecuador and the first full year of profit at Melody Dairies. The company is poised for further growth through its new distributor model and the promising CholineXcel project, targeting infant and prenatal nutrition markets, while continuing to explore opportunities in high-value nutraceutical markets.
Clover Corporation Limited announced a change in the interest of its Key Management Personnel, Andrew Allibon, who has acquired an additional 2,447 ordinary shares through an on-market purchase. This change reflects a slight increase in insider ownership, which may indicate confidence in the company’s future prospects and could positively influence stakeholder perception.
Clover Corporation Limited announced a change in the director’s interest, with Fiona Pearse acquiring 62,996 ordinary shares through an on-market purchase, increasing her total holdings to 149,028 shares. This transaction, valued at $40,050, reflects a strategic move by the director, potentially indicating confidence in the company’s future performance and stability, which could positively impact stakeholder perceptions.
Clover Corporation Limited announced a change in the director’s interest, with Fiona Pearse acquiring an additional 31,000 ordinary shares through an on-market purchase, increasing her total holdings to 86,032 shares. This acquisition reflects a strategic move by the director, potentially signaling confidence in the company’s future performance and stability, which could have positive implications for stakeholders and market perception.
Clover Corporation Limited has announced the details of its 2025 Annual General Meeting (AGM), scheduled for November 18, 2025, to be held in a hybrid format allowing both in-person and online participation. The AGM will provide shareholders an opportunity to engage with the company’s board, discuss the company’s performance, and vote on key resolutions. The company has also released its 2025 Annual Report, which is available on its website. The board recommends shareholders vote in favor of resolutions 2 to 6, while abstaining from a recommendation on resolution 1 due to its nature concerning the remuneration report.
Clover Corporation Limited announced a change in the director’s interest, with Fiona Pearse acquiring an additional 14,492 ordinary shares through an on-market purchase, increasing her total holdings to 55,032 shares. This acquisition reflects a continued commitment to the company and may indicate confidence in its future performance, potentially impacting stakeholders’ perceptions and the company’s market positioning.
Clover Corporation Limited has announced its intention to hold its annual general meeting (AGM) on 18 November 2025. The company has set the closing date for director nominations for 6 October 2025, in accordance with its constitution and ASX listing rules. This meeting is significant for stakeholders as it provides an opportunity for the election of directors, which could influence the company’s strategic direction and governance.
Clover Corporation Limited has announced its annual report for the year ended 31 July 2025. The company has undergone changes in its board of directors with the appointment of Ms Fiona Pearse as a Non-Executive Director starting from 1 August 2025. This change in leadership could potentially impact the company’s strategic direction and operations.
Clover Corporation Limited reported a strong financial performance for the fiscal year 2025, with a 38% increase in net sales revenue to $86 million and a significant rise in net profit after tax to $7 million. The company’s growth was driven by new product launches and improved operational performance, particularly at its Melody Dairies and Ecuador facilities. Clover’s strategic initiatives, including expanding its distribution model and investing in product development, have positioned it well for future growth. The company declared a final dividend of 1 cent per share, reflecting its robust financial health and cash generation capabilities.
Clover Corporation Limited reported a significant financial improvement for the year ended July 31, 2025, with a 38% increase in total revenue to $86 million and a net profit after tax of $7 million, marking a 601% rise from the previous year. This financial growth reflects the company’s strengthened market position and operational success, benefiting stakeholders through increased dividends and a robust financial outlook.
Clover Corporation Limited is set to release its FY25 financial results on September 23, 2025, before the market opens. The company will host a webinar on the same day, featuring presentations by the Managing Director and CEO, Peter Davey, and CFO, Andrew Allibon, who will discuss the year’s business activities and highlights. This announcement is part of Clover’s ongoing efforts to engage with investors and stakeholders, reflecting its commitment to transparency and strategic growth in the nutritional ingredients sector.